Literature DB >> 9627330

In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors.

M Bergström1, T A Bonasera, L Lu, E Bergström, C Backlin, C Juhlin, B Långström.   

Abstract

METHODS: With the purpose of developing a PET imaging agent for tumors of the adrenal cortex, we developed syntheses for 11C-etomidate and its methyl analog, 11C-metomidate. (R)-[O-ethyl-1-11C]Etomidate and (R)-[O-methyl-11C]metomidate were prepared by reaction of the appropriate respective 11C-labeled alkyl iodide and the tetrabutylammonium salt of the carboxylic acid derivative. The specificity of binding to the adrenal cortex was tested through the use of frozen section autoradiography of different tissues of the rat, pig and human. Inhibition of tracer binding was evaluated with etomidate, ketoconazole and metyrapone, well-known inhibitors of enzymes for steroid synthesis. Tracer binding to different human tumor samples was compared to immunohistochemical staining with antibodies for the steroid synthesis enzymes P450 11beta (11beta-hydroxylase), P450 scc (cholesterol side-chain cleavage enzyme), P450 C21 (21 -hydroxylase) and P450 17alpha (17alpha-hydroxylase). Three PET investigations, one with 11C-etomidate and two with 11C-metomidate, were performed in rhesus monkey sections, including the adrenals, liver and kidneys. Time-activity curves were generated from measured tracer uptake in these organs.
RESULTS: In frozen section autoradiography of various tissues, high binding was seen in the adrenal cortex from all species, as well as in the tumors of adrenal cortical origin. The level of liver binding was about 50% of that in the adrenals, whereas that of all other organs was <10% of the adrenal binding. The adrenal binding was blocked by etomidate and ketoconazole at low doses but not by metyrapone. The binding in the adrenal tumor samples correlated with immunostaining for P450 11beta . PET studies in the monkey demonstrated high uptake in the adrenals with excellent visualization. The uptake increased with time without indication of washout. Slightly lower uptake was seen in the liver as compared to the adrenals, and in the late images, no organs other than adrenals and liver were seen.
CONCLUSION: These investigations indicate that 11C-etomidate and 11C-metomidate have the potential to be useful specific agents for the visualization of the normal adrenal cortex and to provide positive identification of adrenal cortical tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627330

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers.

Authors:  Wolfgang Wadsak; Markus Mitterhauser; Gundula Rendl; Matthias Schuetz; Leonhard Key Mien; Dagmar E Ettlinger; Robert Dudczak; Kurt Kletter; Georgios Karanikas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

3.  Radiosynthesis of [124I]iodometomidate and biological evaluation using small-animal PET.

Authors:  Herbert Kvaternik; Thomas Wanek; Friedrich Hammerschmidt; Ilse Zolle; Reingard Aigner; Claudia Kuntner
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

Review 4.  Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.

Authors:  Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke
Journal:  Curr Hypertens Rep       Date:  2019-09-03       Impact factor: 5.369

Review 5.  Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.

Authors:  Peter J Fuller
Journal:  Clin Biochem Rev       Date:  2013-11

Review 6.  11C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature.

Authors:  Stanley M Chen Cardenas; Prasanna Santhanam
Journal:  Endocrine       Date:  2020-09-04       Impact factor: 3.633

Review 7.  Metomidate-based imaging of adrenal masses.

Authors:  S Hahner; A Sundin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 8.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

9.  In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats.

Authors:  Markus Mitterhauser; Wolfgang Wadsak; Leila Wabnegger; Werner Sieghart; Helmut Viernstein; Kurt Kletter; Robert Dudczak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

10.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.

Authors:  Georg Zettinig; Markus Mitterhauser; Wolfgang Wadsak; Alexander Becherer; Christian Pirich; Heinrich Vierhapper; Bruno Niederle; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.